NBI-921352, a First-in-Class, Na V 1.6 Selective, Sodium Channel Inhibitor That Prevents Seizures in Scn8a Gain-of-Function Mice, and Wild-Type Mice and Rats
Authors:
Preprint
Abstract
NBI-921352 (formerly XEN901) is a novel sodium channel inhibitor designed to specifically target Na V 1.6 channels. Such a molecule provides a precision-medicine approach to target SCN8A -related epilepsy syndromes ( SCN8A -RES), where gain-of-function (GoF) mutations lead to excess Na V 1.6 sodium current, or other indications where Na V 1.6 mediated hyper-excitability contributes to disease (Gardella and Moller, 2019; Johannesen et al., 2019; Veeramah et al., 2012). NBI-921352 is a potent inhibitor of Na V 1.6 (IC 50 0.051 µM), with exquisite selectivity over other sodium channel isoforms (selectivity ratios of 756X for Na V 1.1, 134X for Na V 1.2, 276X for Na V 1.7, and >583X for Na V 1.3, Na V 1.4, and Na V 1.5). NBI-921352 is a state-dependent inhibitor, preferentially inhibiting activated (inactivated or open) channels. The state dependence leads to potent stabilization of inactivation, inhibiting Na V 1.6 currents, including resurgent and persistent Na V 1.6 currents, while sparing the closed/rested channels. The isoform-selective profile of NBI-921352 led to a robust inhibition of action-potential firing in glutamatergic excitatory pyramidal neurons, while sparing fast-spiking inhibitory interneurons, where Na V 1.1 predominates. Oral administration of NBI-921352 prevented electrically induced seizures in a Scn8a GoF mouse, as well as in wild-type mouse and rat seizure models. NBI-921352 was effective in preventing seizures at lower brain and plasma concentrations than commonly prescribed sodium channel inhibitor antiseizure medicines (ASMs) carbamazepine, phenytoin, and lacosamide. NBI-921352 was well tolerated at higher multiples of the effective plasma and brain concentrations than those ASMs. NBI-921352 is entering phase II proof-of-concept trials for the treatment of SCN8A- developmental epileptic encephalopathy ( SCN8A -DEE) and adult focal-onset seizures.Keywords
All Related Versions
- Published version: eLife, 11.
This publication has 45 references indexed in Scilit:
- De Novo Pathogenic SCN8A Mutation Identified by Whole-Genome Sequencing of a Family Quartet Affected by Infantile Epileptic Encephalopathy and SUDEPThe American Journal of Human Genetics, 2012
- Neuronal voltage-gated ion channels are genetic modifiers of generalized epilepsy with febrile seizures plusNeurobiology of Disease, 2011
- NaV1.1 channels and epilepsyThe Journal of Physiology, 2010
- Role of Axonal NaV1.6 Sodium Channels in Action Potential Initiation of CA1 Pyramidal NeuronsJournal of Neurophysiology, 2008
- Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancyNature Neuroscience, 2006
- De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of InfancyThe American Journal of Human Genetics, 2001
- A Met-to-Val mutation in the skeletal muscle Na+ channel α-subunit in hyperkalaemic periodic paralysisNature, 1991
- Identification of a mutation in the gene causing hyperkalemic periodic paralysisCell, 1991
- Lidocaine block of cardiac sodium channels.Journal of General Physiology, 1983
- Molecular Mechanisms of Nerve Block by Local AnestheticsAnesthesiology, 1976